Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 3/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 4/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577379 | 0.90 | CCR3 (0.53) | CHRM3CCR3CCR5ROCK2LMNA | |
| SCHEMBL5577681 | 0.90 | CCR2 (0.56) | CHRM3KCNH2CCR2 | |
| SCHEMBL5577672 | 0.88 | KMT2A (0.51) | CHRM3CCR3CCR5MEN1KMT2A | |
| SCHEMBL5577618 | 0.87 | CHRM3 (0.60) | CHRM3MCHR1KCNH2MEN1KMT2A | |
| SCHEMBL5577463 | 0.87 | MCHR1 (0.61) | CHRM3CCR5MCHR1KCNH2MEN1 | |
| SCHEMBL5577652 | 0.87 | CCR5 (0.63) | CCR3CCR5MCHR1KMT2AROCK2 | |
| SCHEMBL5577897 | 0.82 | GAA (0.54) | CHRM3MCHR1KCNH2LMNAACKR3 | |
| SCHEMBL5577392 | 0.81 | ALDH1A1 (0.62) | CHRM3CCR5MCHR1KMT2ALMNA | |
| SCHEMBL5577611 | 0.81 | MEN1 (0.59) | CHRM3MEN1KMT2ACCR2CXCR3 | |
| SCHEMBL5577295 | 0.80 | SMN1; SMN2 (0.53) | CHRM3CCR5MCHR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CHRM3 2099/4885CCR3 120/4885CCR5 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.